Literature DB >> 22183642

Probability of C282Y homozygosity decreases as liver transaminase activities increase in participants with hyperferritinemia in the hemochromatosis and iron overload screening study.

Paul C Adams1, Mark Speechley, James C Barton, Christine E McLaren, Gordon D McLaren, John H Eckfeldt.   

Abstract

UNLABELLED: Hemochromatosis is considered by many to be an uncommon disorder, although the prevalence of HFE (High Iron) 282 Cys → Tyr (C282Y) homozygosity is relatively high in Caucasians. Liver disease is one of the most consistent findings in advanced iron overload resulting from hemochromatosis. Liver clinics are often thought to be ideal venues for diagnosis of hemochromatosis, but diagnosis rates are often low. The Hemochromatosis and Iron Overload Screening (HEIRS) Study screened 99,711 primary care participants in North America for iron overload using serum ferritin and transferrin saturation measurements and HFE genotyping. In this HEIRS substudy, serum hepatic transaminases activities (e.g., alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) were compared between 162 C282Y homozygotes and 1,367 nonhomozygotes with serum ferritin levels >300 μg/L in men and >200 μg/L in women and transferrin saturation >45% in women and 50% in men. The probability of being a C282Y homozygote was determined for AST and ALT ranges. Mean ALT and AST activities were significantly lower in C282Y homozygotes than nonhomozygotes. The probability of being a C282Y homozygote increased as the ALT and AST activities decreased.
CONCLUSION: Patients with hyperferritinemia are more likely to be C282Y homozygotes if they have normal liver transaminase activities. This paradox could explain the low yields of hemochromatosis screening reported by some liver clinics.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22183642      PMCID: PMC3355194          DOI: 10.1002/hep.25538

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

1.  Pursuing mild elevations of liver enzyme values to exclude hemochromatosis.

Authors:  T J Meyer; D Van Kooten; A V Prochazka
Journal:  South Med J       Date:  1990-11       Impact factor: 0.954

2.  Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) study.

Authors:  Paul C Adams; David M Reboussin; Cathie Leiendecker-Foster; Godfrey C Moses; Gordon D McLaren; Christine E McLaren; Fitzroy W Dawkins; Ishmael Kasvosve; Ron T Acton; James C Barton; Dan Zaccaro; Emily L Harris; Richard Press; Henry Chang; John H Eckfeldt
Journal:  Clin Chem       Date:  2005-04-15       Impact factor: 8.327

3.  Predictive value of family history in diagnosis of hereditary hemochromatosis.

Authors:  N Assy; P C Adams
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

4.  Evaluation of blood donors with elevated serum alanine aminotransferase levels.

Authors:  L S Friedman; J L Dienstag; E Watkins; C A Hinkle; J A Spiers; S V Rieder; C E Huggins
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

5.  The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients.

Authors:  J E Hay; A J Czaja; J Rakela; J Ludwig
Journal:  Hepatology       Date:  1989-02       Impact factor: 17.425

6.  Biochemical liver profile in hemochromatosis. A survey of 100 patients.

Authors:  E Lin; P C Adams
Journal:  J Clin Gastroenterol       Date:  1991-06       Impact factor: 3.062

Review 7.  A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation.

Authors:  Paul C Adams; James C Barton
Journal:  J Hepatol       Date:  2011-02-24       Impact factor: 25.083

8.  Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients.

Authors:  S Daniel; T Ben-Menachem; G Vasudevan; C K Ma; M Blumenkehl
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

9.  Hemochromatosis and iron-overload screening in a racially diverse population.

Authors:  Paul C Adams; David M Reboussin; James C Barton; Christine E McLaren; John H Eckfeldt; Gordon D McLaren; Fitzroy W Dawkins; Ronald T Acton; Emily L Harris; Victor R Gordeuk; Catherine Leiendecker-Foster; Mark Speechley; Beverly M Snively; Joan L Holup; Elizabeth Thomson; Phyliss Sholinsky
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

10.  Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase.

Authors:  M Bhavnani; D Lloyd; A Bhattacharyya; J Marples; P Elton; M Worwood
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

View more
  5 in total

1.  Predicting C282Y homozygote genotype for hemochromatosis using serum ferritin and transferrin saturation values from 44,809 participants of the HEIRS study.

Authors:  Andrew Lim; Mark Speechley; Paul C Adams
Journal:  Can J Gastroenterol Hepatol       Date:  2014-10

2.  Elevated serum transaminase activities were associated with increased serum levels of iron regulatory hormone hepcidin and hyperferritinemia risk.

Authors:  Peng An; Hao Wang; Qian Wu; Xin Guo; Aimin Wu; Zhou Zhang; Di Zhang; Xiaochen Xu; Qianyun Mao; Xiaoyun Shen; Lihong Zhang; Zhiqi Xiong; Lin He; Yun Liu; Junxia Min; Daizhan Zhou; Fudi Wang
Journal:  Sci Rep       Date:  2015-08-20       Impact factor: 4.379

3.  Hereditary hemochromatosis.

Authors:  Stephen A Geller; Fernando P F de Campos
Journal:  Autops Case Rep       Date:  2015-03-30

4.  Genetic disruption of NRF2 promotes the development of necroinflammation and liver fibrosis in a mouse model of HFE-hereditary hemochromatosis.

Authors:  Tiago L Duarte; Carolina Caldas; Ana G Santos; Sandro Silva-Gomes; Andreia Santos-Gonçalves; Maria João Martins; Graça Porto; José Manuel Lopes
Journal:  Redox Biol       Date:  2016-12-01       Impact factor: 11.799

5.  EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).

Authors:  Graça Porto; Pierre Brissot; Dorine W Swinkels; Heinz Zoller; Outi Kamarainen; Simon Patton; Isabel Alonso; Michael Morris; Steve Keeney
Journal:  Eur J Hum Genet       Date:  2015-07-08       Impact factor: 4.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.